These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 19299654)

  • 1. Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7.
    Furlan I; Batz C; Flotho C; Mohr B; Lübbert M; Suttorp M; Niemeyer CM
    Blood; 2009 Mar; 113(12):2867-8. PubMed ID: 19299654
    [No Abstract]   [Full Text] [Related]  

  • 2. Sustained remission with azacitidine monotherapy and an aberrant precursor B-lymphoblast population in juvenile myelomonocytic leukemia.
    Hashmi SK; Punia JN; Marcogliese AN; Gaikwad AS; Fisher KE; Roy A; Rao P; Lopez-Terrada DH; Ringrose J; Loh ML; Niemeyer CM; Rau RE
    Pediatr Blood Cancer; 2019 Oct; 66(10):e27905. PubMed ID: 31250550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group.
    Cseh A; Niemeyer CM; Yoshimi A; Dworzak M; Hasle H; van den Heuvel-Eibrink MM; Locatelli F; Masetti R; Schmugge M; Groß-Wieltsch U; Candás A; Kulozik AE; Olcay L; Suttorp M; Furlan I; Strahm B; Flotho C
    Blood; 2015 Apr; 125(14):2311-3. PubMed ID: 25838281
    [No Abstract]   [Full Text] [Related]  

  • 4. Azacitidine as a bridge to transplantation in juvenile myelomonocytic leukemia.
    Takebayashi A; Yamamoto M; Igarashi K; Muramatsu H; Kawasaki Y
    Pediatr Int; 2022 Jan; 64(1):e14929. PubMed ID: 35119175
    [No Abstract]   [Full Text] [Related]  

  • 5. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
    Flotho C; Sommer S; Lübbert M
    Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole Genome MBD-seq reveals different CpG methylation patterns in Azacytidine-treated Juvenile Myelomonocytic Leukaemia (JMML) patients.
    Leoncini PP; Vitullo P; Di Florio F; Tocco V; Cefalo MG; Pitisci A; Girardi K; Niemeyer C; Locatelli F; Bertaina A
    Br J Haematol; 2018 Sep; 182(6):909-912. PubMed ID: 28771681
    [No Abstract]   [Full Text] [Related]  

  • 7. Gene mutations do not operate in a vacuum: the increasing importance of epigenetics in juvenile myelomonocytic leukemia.
    Flotho C
    Epigenetics; 2019 Mar; 14(3):236-244. PubMed ID: 30773984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemia.
    Hecht A; Meyer J; Chehab FF; White KL; Magruder K; Dvorak CC; Loh ML; Stieglitz E
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27948. PubMed ID: 31347788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A paediatric case of successful non-myeloablative bone marrow transplantation after azacitidine therapy for non-Down syndrome acute megakaryoblastic leukaemia with monosomy 7.
    Koga Y; Oba U; Kato W; Ono H; Nakashima K; Takada H
    Pediatr Transplant; 2016 Sep; 20(6):868-70. PubMed ID: 27384975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Two Juvenile Myelomonocytic Leukemia Patients According to Clinical and Genetic Features.
    Tüfekçi Ö; Ören H; Demir Yenigürbüz F; Gözmen S; Karapınar TH; İrken G
    Turk J Haematol; 2015 Jun; 32(2):175-9. PubMed ID: 26316488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azacitidine is effective for targeting leukemia-initiating cells in juvenile myelomonocytic leukemia.
    Krombholz CF; Gallego-Villar L; Sahoo SS; Panda PK; Wlodarski MW; Aumann K; Hartmann M; Lipka DB; Daskalakis M; Plass C; Niemeyer CM; Erlacher M; Flotho C
    Leukemia; 2019 Jul; 33(7):1805-1810. PubMed ID: 30679798
    [No Abstract]   [Full Text] [Related]  

  • 12. A retrospective analysis of azacitidine treatment for juvenile myelomonocytic leukemia.
    Honda Y; Muramatsu H; Nanjo Y; Hirabayashi S; Meguro T; Yoshida N; Kakuda H; Ozono S; Wakamatsu M; Moritake H; Yasui M; Sano H; Manabe A; Sakashita K
    Int J Hematol; 2022 Feb; 115(2):263-268. PubMed ID: 34714526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome.
    Olk-Batz C; Poetsch AR; Nöllke P; Claus R; Zucknick M; Sandrock I; Witte T; Strahm B; Hasle H; Zecca M; Stary J; Bergstraesser E; De Moerloose B; Trebo M; van den Heuvel-Eibrink MM; Wojcik D; Locatelli F; Plass C; Niemeyer CM; Flotho C;
    Blood; 2011 May; 117(18):4871-80. PubMed ID: 21406719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RASA4 undergoes DNA hypermethylation in resistant juvenile myelomonocytic leukemia.
    Poetsch AR; Lipka DB; Witte T; Claus R; Nöllke P; Zucknick M; Olk-Batz C; Fluhr S; Dworzak M; De Moerloose B; Starý J; Zecca M; Hasle H; Schmugge M; van den Heuvel-Eibrink MM; Locatelli F; Niemeyer CM; Flotho C; Plass C
    Epigenetics; 2014 Sep; 9(9):1252-60. PubMed ID: 25147919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of azacitidine on matrix metalloproteinase-9 in acute myeloid leukemia and myelodysplasia.
    Bernal T; Moncada-Pazos A; Soria-Valles C; Gutiérrez-Fernández A
    Exp Hematol; 2013 Feb; 41(2):172-9. PubMed ID: 23085464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial.
    Niemeyer CM; Flotho C; Lipka DB; Starý J; Rössig C; Baruchel A; Klingebiel T; Micalizzi C; Michel G; Nysom K; Rives S; Schmugge Liner M; Zecca M; Schönung M; Baumann I; Nöllke P; Benettaib B; Biserna N; Poon J; Simcock M; Patturajan M; Menezes D; Gaudy A; van den Heuvel-Eibrink MM; Locatelli F
    Blood Adv; 2021 Jul; 5(14):2901-2908. PubMed ID: 34297046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.
    Meldi K; Qin T; Buchi F; Droin N; Sotzen J; Micol JB; Selimoglu-Buet D; Masala E; Allione B; Gioia D; Poloni A; Lunghi M; Solary E; Abdel-Wahab O; Santini V; Figueroa ME
    J Clin Invest; 2015 May; 125(5):1857-72. PubMed ID: 25822018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia.
    Locatelli F; Algeri M; Merli P; Strocchio L
    Expert Rev Hematol; 2018 Feb; 11(2):129-143. PubMed ID: 29279013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypermethylation of the 5' CpG island of the FHIT gene is associated with hyperdiploid and translocation-negative subtypes of pediatric leukemia.
    Zheng S; Ma X; Zhang L; Gunn L; Smith MT; Wiemels JL; Leung K; Buffler PA; Wiencke JK
    Cancer Res; 2004 Mar; 64(6):2000-6. PubMed ID: 15026336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Graft versus leukemia effect against juvenile myelomonocytic leukemia after unrelated cord blood transplantation.
    Tanoshima R; Goto H; Yanagimachi M; Kajiwara R; Kuroki F; Yokota S
    Pediatr Blood Cancer; 2008 Mar; 50(3):665-7. PubMed ID: 17437289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.